These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 19194337)

  • 1. Improving the prediction of medication compliance: the example of bisphosphonates for osteoporosis.
    Curtis JR; Xi J; Westfall AO; Cheng H; Lyles K; Saag KG; Delzell E
    Med Care; 2009 Mar; 47(3):334-41. PubMed ID: 19194337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A retrospective analysis of extended-interval dosing and the impact on bisphosphonate compliance in the US Military Health System.
    Devine J; Trice S; Finney Z; Yarger S; Nwokeji E; Linton A; Davies W
    Osteoporos Int; 2012 Apr; 23(4):1415-24. PubMed ID: 21786005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of refracture associated with compliance and persistence with bisphosphonate therapy in Taiwan.
    Soong YK; Tsai KS; Huang HY; Yang RS; Chen JF; Wu PC; Huang KE
    Osteoporos Int; 2013 Feb; 24(2):511-21. PubMed ID: 22588182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adherence to osteoporosis medications amongst Singaporean patients.
    Cheen MH; Kong MC; Zhang RF; Tee FM; Chandran M
    Osteoporos Int; 2012 Mar; 23(3):1053-60. PubMed ID: 21503813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral bisphosphonate compliance and persistence: a matter of choice?
    Silverman SL; Schousboe JT; Gold DT
    Osteoporos Int; 2011 Jan; 22(1):21-6. PubMed ID: 20458571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between refill compliance to oral bisphosphonate treatment, incident fractures, and health care costs--an analysis using national health databases.
    Olsen KR; Hansen C; Abrahamsen B
    Osteoporos Int; 2013 Oct; 24(10):2639-47. PubMed ID: 23604250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Descriptive analysis of concomitant prescription medication patterns from 1999 to 2004 among US women receiving daily or weekly oral bisphosphonate therapy.
    Gold DT; Bonnick SL; Amonkar MM; Kamel HK; Agarwal S; Zaidi M
    Gend Med; 2008 Dec; 5(4):374-84. PubMed ID: 19108810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are long-term bisphosphonate users a reality? Dose years for current bisphosphonate users assessed using the danish national prescription database.
    Abrahamsen B
    Osteoporos Int; 2013 Jan; 24(1):369-72. PubMed ID: 22572963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis.
    Cramer JA; Amonkar MM; Hebborn A; Altman R
    Curr Med Res Opin; 2005 Sep; 21(9):1453-60. PubMed ID: 16197664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors contributing to compliance with osteoporosis medication.
    Kertes J; Dushenat M; Vesterman JL; Lemberger J; Bregman J; Friedman N
    Isr Med Assoc J; 2008 Mar; 10(3):207-13. PubMed ID: 18494234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimating bisphosphonate use and fracture reduction among US women aged 45 years and older, 2001-2008.
    Siris ES; Pasquale MK; Wang Y; Watts NB
    J Bone Miner Res; 2011 Jan; 26(1):3-11. PubMed ID: 20662073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101,038 new bisphosphonate users.
    Curtis JR; Westfall AO; Cheng H; Lyles K; Saag KG; Delzell E
    J Bone Miner Res; 2008 Sep; 23(9):1435-41. PubMed ID: 18442318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary non-adherence to bisphosphonates in an integrated healthcare setting.
    Reynolds K; Muntner P; Cheetham TC; Harrison TN; Morisky DE; Silverman S; Gold DT; Vansomphone SS; Wei R; O'Malley CD
    Osteoporos Int; 2013 Sep; 24(9):2509-17. PubMed ID: 23595561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prior adherence to statins is a predictor of subsequent adherence and persistence to oral, but not parenteral, osteoporosis medications.
    Gupta A; Lin M; McAlister FA; Ye C
    J Bone Miner Metab; 2021 Jul; 39(4):712-718. PubMed ID: 33821305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic review of persistence and compliance with bisphosphonates for osteoporosis.
    Cramer JA; Gold DT; Silverman SL; Lewiecki EM
    Osteoporos Int; 2007 Aug; 18(8):1023-31. PubMed ID: 17308956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world persistence and adherence with oral bisphosphonates for osteoporosis: a systematic review.
    Fatoye F; Smith P; Gebrye T; Yeowell G
    BMJ Open; 2019 Apr; 9(4):e027049. PubMed ID: 30987990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors for fracture among current, persistent users of bisphosphonates.
    LeBlanc ES; Rosales AG; Balasubramanian A; O'Malley CD; Egbuna O; Friess D; Perrin NA
    Osteoporos Int; 2015 Feb; 26(2):713-25. PubMed ID: 25354654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of interactive voice response technology on primary adherence to bisphosphonate therapy: a randomized controlled trial.
    Cizmic AD; Heilmann RM; Milchak JL; Riggs CS; Billups SJ
    Osteoporos Int; 2015 Aug; 26(8):2131-6. PubMed ID: 25956282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physicians' perspectives on the treatment of osteoporosis patients with bisphosphonates.
    Gu T; Eisenberg Lawrence DF; Stephenson JJ; Yu J
    Clin Interv Aging; 2016; 11():1-8. PubMed ID: 26929609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adherence with brand versus generic bisphosphonates among osteoporosis patients: a new-user cohort study in the French National Healthcare Insurance database.
    Viprey M; Xue Y; Rousseau A; Payet C; Chapurlat R; Caillet P; Dima A; Schott AM
    Sci Rep; 2020 May; 10(1):7446. PubMed ID: 32366863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.